Chronic inflammation is often the result of treatment failure and drug resistance. Located around blood vessels, mast cells are primary responders in inflammation by releasing pre-formed as well as de novo synthesized various inflammatory mediators, including histamine, cytokines, and chemokines upon allergen cross-linking of high affinity receptors for IgE (Fc?RI). In addition, activated mast cells can release the sphingolipid metabolite sphingosine-1-phosphate (S1P), generated upon sphingosine kinase (SphK) activation. Secreted S1P can bind to its own receptors, such as the type 2 receptor (S1P2) expressed on mast cells. Several mouse models of chronic inflammatory disorders have established an early increase in mast cell number in inflammatory foci, suggesting their early intervention in the process. We have shown that mast cell S1P2 is essential to the early events associated with acute signs of allergic inflammation, among which edema surrounding the blood vessels in the lungs. Edema promotes subsequent recruitment of inflammatory cells, also favored by increased number of blood vessels, features commonly observed in chronic inflammation. We are proposing to study the contribution of mast cell-expressed S1P2 in the disease progression using mouse models of mast cell-mediated pulmonary inflammation and define how it could lead to persistent inflammation. Using pharmacological, molecular and genetic approaches, we have discovered a new signaling pathway linking S1P2 to Stat3 transcription factor and how disrupting this pathway may potentially abrogate aspects of remodeling observed in chronic inflammation. The objectives of this application are: to establish the role of S1P2 in initiating inflammatory cell infiltration and propagating inflammation~ to elucidate the newly identified signaling pathway and its relevance to remodeling~ to develop in vivo models targeting the mast cell/S1P/ S1P2 axis in an attempt to prevent features associated with chronic inflammatory disorders. Since targeting individual mediators has failed to prevent sustained inflammation, we anticipate our proposed studies will lead to a better understanding of its underlying mechanisms and pave the way for more mechanistically tailored therapies targeting local regulatory pathways in inflammation with a central role for mast cell expressed S1P2.

Public Health Relevance

Chronic inflammation is prevalent in many diseases responsible for the majority of health-care costs associated with these drug-resistant diseases. We are proposing that the type 2 receptor for a multifunctional mediator, sphingosine-1-phosphate, and its expression on mast cells which are primary responders in allergic disorders, exert a central function in initiating and propagating many features observed in inflamed tissues. We anticipate this innovative concept will lead to tailored therapies targeting local regulatory pathways in chronic inflammation for which there is no cure.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01AI095494-04
Application #
8681300
Study Section
Innate Immunity and Inflammation (III)
Program Officer
Dong, Gang
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of South Carolina at Columbia
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Columbia
State
SC
Country
United States
Zip Code
29208
Kolawole, Elizabeth Motunrayo; McLeod, Jamie Josephine Avila; Ndaw, Victor et al. (2016) Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects. J Immunol 196:1461-70
Abebayehu, Daniel; Spence, Andrew J; Qayum, Amina Abdul et al. (2016) Lactic Acid Suppresses IL-33-Mediated Mast Cell Inflammatory Responses via Hypoxia-Inducible Factor-1α-Dependent miR-155 Suppression. J Immunol 197:2909-17
Paranjape, Anuya; Chernushevich, Oksana; Qayum, Amina Abdul et al. (2016) Dexamethasone rapidly suppresses IL-33-stimulated mast cell function by blocking transcription factor activity. J Leukoc Biol 100:1395-1404
Qayum, Amina Abdul; Paranjape, Anuya; Abebayehu, Daniel et al. (2016) IL-10-Induced miR-155 Targets SOCS1 To Enhance IgE-Mediated Mast Cell Function. J Immunol 196:4457-67
Chumanevich, Alena; Wedman, Piper; Oskeritzian, Carole A (2016) Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor 2 Axis Can Promote Mouse and Human Primary Mast Cell Angiogenic Potential through Upregulation of Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-2. Mediators Inflamm 2016:1503206
Oskeritzian, Carole A; Hait, Nitai C; Wedman, Piper et al. (2015) The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. J Allergy Clin Immunol 135:1008-18.e1
Oskeritzian, Carole A (2015) Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer. Mol Immunol 63:104-12
Fernando, Josephine; Faber, Travis W; Pullen, Nicholas A et al. (2013) Genotype-dependent effects of TGF-*1 on mast cell function: targeting the Stat5 pathway. J Immunol 191:4505-13
Garg, Koyal; Pullen, Nicholas A; Oskeritzian, Carole A et al. (2013) Macrophage functional polarization (M1/M2) in response to varying fiber and pore dimensions of electrospun scaffolds. Biomaterials 34:4439-51
Price, Megan M; Oskeritzian, Carole A; Falanga, Yves T et al. (2013) A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol 131:501-11.e1